Challenges and Opportunities: Pharmaceutical and Medical Technology Industry Trends
New Brunswick, NJ, October 7, 2002 — Decisions made today in New Jersey are shaping the future of human health — both here in the Garden State and around the globe. As a result of the unheralded success in research and innovation, the pharmaceutical and medical technology industry is now poised to conquer some of […]
Who Will Be Our Healers? The Case for Linking Academics and a Job
New Brunswick, NJ, October 7, 2002 — A frequent lament among American employers is the lack of skilled workers to meet the ever-changing needs of the new economy. In fact, survey after survey reports that finding and retaining qualified workers is the number one issue for U.S. industry today.
The High Cost of Low Drug Prices: The Medicare Prescription Drug and Modernization Act
New Brunswick, NJ, October 7, 2002 — The ink is barely dry on the new “Medicare Prescription Drug and Modernization Act” and already opponents of the law are seeking radical changes to it. In addition to the AARP, Families USA, citizen lobbying groups, and members of Congress have recently called for amendments to the new […]
New Jersey’s Pharmaceutical & Medical Technology Industry: The Picture of Health
New Brunswick, NJ, October 7, 2002 — For the seventh consecutive year, New Jersey’s pharmaceutical and medical technology industry emerged as New Jersey’s economic powerhouse and continues to expand. That conclusion was validated by the HealthCare Institute of New Jersey’s annual economic study, “Healthy Opportunities,” which was recently unveiled at an unprecedented meeting with key […]
New Jersey Must Champion Its Life Science Cluster to Remain ‘Medicine Chest of the World’
New Brunswick, NJ, October 7, 2002 — The pharmaceutical and medical technology industry has long been an economic engine in New Jersey, with companies such as Johnson & Johnson and Merck arriving more than a century ago. Now, a groundbreaking study conducted by renowned Harvard Professor Michael E. Porter, underscores the importance of this industry […]
New Jersey Is Still the World’s Cure Corridor
New Brunswick, NJ, October 7, 2002 — A recent article in the Philadelphia Inquirer boldly proclaimed, “Pennsylvania is now the nation’s largest producer of drugs, surpassing New Jersey.” That’s quite a statement. Unfortunately, by most relevant measures, it is more fiction than fact.
New Economic Impact Report Finds a Healthy Pharmaceutical and Medical Technology Industry in New Jersey
New Brunswick, NJ, February 10, 2002 — While some New Jersey companies were laying off workers in 2001, New Jersey’s pharmaceutical and medical technology industry created more than 3,000 jobs during the year. The HealthCare Institute of New Jersey announced these findings and others in conjunction with the release of a study conducted by PricewaterhouseCoopers […]
New Jersey Pharmaceutical Companies Developed 53 Percent of FDA-Approved New Medicines in 2001
New Brunswick, NJ, January 28, 2002 — New Jersey-based pharmaceutical companies extended their decade-long dominance of the industry by developing 15 of the 24 new drugs approved by the U.S. Food and Drug Administration (FDA) in 2001. They were also responsible for the development of two of the eight newly approved biologics.
New Jersey Pharmaceutical Companies Support NJ Medicare Resolution
New Brunswick, NJ, October 1, 2001 — New Jersey’s pharmaceutical companies support New Jersey Senate Concurrent Resolution 116, which calls for Congress to enact legislation to provide prescription drug coverage for Medicare recipients without penalizing states, such as New Jersey, that have their own pharmaceutical assistance programs for their elderly residents.
Former New Jersey Congressman Bob Franks Named President of HealthCare Institute of New Jersey
New Brunswick, NJ, July 5, 2001 — Former New Jersey Congressman Bob Franks has been appointed President of the HealthCare Institute of New Jersey, the organization’s Board of Trustees announced today. Mr. Franks assumes this position August 1, succeeding William H. Tremayne, who is retiring.